Gilead news from FiercePharma
News
Docs back Viread for hepatitis B
Analysts are chatting up Gilead Science's HIV drug Viread as a treatment for hepatitis B. Currently under FDA review for that indication, Viread already has the backing of four out of five doctors, Read more...
Brazil mulls patent-busting on Tenofovir
The Brazilian government recently deemed the anti-HIV med Tenofovir a "public interest." That's code for, "We're thinking about issuing a compulsory license for this drug." Under Read more...
Pfizer, Roche suffer as big drugs falter
Today's earnings roundup is a snapshot of pharma's challenges--generic Read more...
Get more Gilead coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets